> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss Rexulti for Alzheimer’s Agitation
- URL: https://www.fdaweb.com/panel-to-discuss-rexulti-for-alzheimers-agitation/
- Published: 2023-03-30T12:00:00.000Z
- Updated: 2026-09-14T18:23:01.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5154106

*Federal Register* notice: FDA has announced a 4/14 joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee. Panel members are scheduled to discuss an Otsuka Pharmaceutical and Lundbeck supplemental NDA for Rexulti (brexpiprazole) tablets for treating agitation associated with Alzheimer’s dementia. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2023-03-30/pdf/2023-06577.pdf?ref=fdaweb.com).